UPDATED: Clovis buys EOS for $200m after 2-year interest in lucitanib
This article was originally published in Scrip
Executive Summary
Clovis Oncology's surging stock price gave the company the value it needed to acquire EOS for $10m in cash and $190m in Clovis common shares, and to access the private Italian firm's cancer drug lucitanib, which Boulder, Colorado-based Clovis has been tracking for two years.
You may also be interested in...
Finance Watch: 5AM, Longevity Close Funds, New Incubators Launch To Support Early-Stage Companies
News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.
Finance Watch: Structure Launches Third And Largest US Biopharma IPO Of 2023
Public Company Edition: Structure Therapeutics’ upsized initial public offering raises $161.1m, surpassing proposed terms for up to $134.3m. Also, Pliant capitalizes on good data with a $287.5m follow-on offering, while Magenta seeks strategic alternatives and Instil reveals more job cuts.
Focus On Execution Pays Off, Sets BMS Up For Growth In 2023
Revenue declined in 2022 but the company expects it to increase 2% this year, offsetting an anticipated $3.5bn drop in Revlimid sales as new launches generate $4bn in 2023.